Literature DB >> 16314752

No genetic association between PCSK9 polymorphisms and Alzheimer's disease and plasma cholesterol level in Japanese patients.

Nobuto Shibata1, Tohru Ohnuma, Shinji Higashi, Maiko Higashi, Chie Usui, Taku Ohkubo, Tomoko Watanabe, Ritsuko Kawashima, Akiyoshi Kitajima, Akira Ueki, Masatsugu Nagao, Heii Arai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16314752     DOI： 10.1097/00041444-200512000-00004

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN： 0955-8829            Impact factor:   2.458


× No keyword cloud information.
  7 in total

1.  PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling.

Authors:  Kai Kysenius; Pranuthi Muggalla; Kert Mätlik; Urmas Arumäe; Henri J Huttunen
Journal:  Cell Mol Life Sci       Date:  2012-04-06       Impact factor: 9.261

2.  Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial.

Authors:  Robert P Giugliano; Francois Mach; Kenton Zavitz; Christopher Kurtz; Jingjing Schneider; Huei Wang; Anthony Keech; Terje R Pedersen; Marc S Sabatine; Peter S Sever; Narimon Honarpour; Scott M Wasserman; Brian R Ott
Journal:  Clin Cardiol       Date:  2017-02-16       Impact factor: 2.882

3.  PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population.

Authors:  Iris Postmus; Stella Trompet; Anton J M de Craen; Brendan M Buckley; Ian Ford; David J Stott; Naveed Sattar; P Eline Slagboom; Rudi G J Westendorp; J Wouter Jukema
Journal:  J Lipid Res       Date:  2013-02       Impact factor: 5.922

4.  The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer's disease progression (Review).

Authors:  Qi Wu; Zhi-Han Tang; Juan Peng; Ling Liao; Li-Hong Pan; Chun-Yan Wu; Zhi-Sheng Jiang; Gui-Xue Wang; Lu-Shan Liu
Journal:  Biomed Rep       Date:  2013-12-30

Review 5.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders.

Authors:  Emma M O'Connell; Falk W Lohoff
Journal:  Front Neurosci       Date:  2020-06-12       Impact factor: 4.677

6.  Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer's Disease.

Authors:  Maria Pia Adorni; Massimiliano Ruscica; Nicola Ferri; Franco Bernini; Francesca Zimetti
Journal:  Front Aging Neurosci       Date:  2019-05-22       Impact factor: 5.750

Review 7.  Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.

Authors:  Marianne Abifadel; Sandy Elbitar; Petra El Khoury; Youmna Ghaleb; Mélody Chémaly; Marie-Line Moussalli; Jean-Pierre Rabès; Mathilde Varret; Catherine Boileau
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.967
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.